0K2H.LSE Moleculin Biotech, Inc.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Is 0K2H.LSE undervalued?

Graham number

The Graham number of Moleculin Biotech, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Moleculin Biotech, Inc. fundamental analysis

No fundamental analysis for Moleculin Biotech, Inc. yet.

Moleculin Biotech, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription mo…

Full company profile